financetom
Business
financetom
/
Business
/
Bank of Nova Scotia Has 'Narrow Path' to Outperform in Uncertain Macroeconomic Landscape, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bank of Nova Scotia Has 'Narrow Path' to Outperform in Uncertain Macroeconomic Landscape, BofA Says
Mar 31, 2025 9:16 AM

11:42 AM EDT, 03/31/2025 (MT Newswires) -- Bank of Nova Scotia ( BNS ) has a "relatively narrow path" to outperform amid the tariff-driven uncertain macroeconomic environment, BofA Securities said in a note Monday.

The bank is also facing headwinds related to its exposure to Mexico and Latin America, below-average common equity tier 1 capital compared with peers, and execution risk tied to its turnaround story, BofA said.

BofA also noted that its meetings with the management teams of Canada's biggest banks indicated stalled customer activity as companies wait for clarity on US tariffs and possible potential actions from the new Canadian government following the federal elections to be held on April 28.

"We believe expectations for policy support have helped investor sentiment and driven resiliency in Canadian bank stocks," BofA said. "Management teams also appear to be taking comfort in the potential for policy actions that would temper credit deterioration on the back of tariffs."

BofA downgraded Bank of Nova Scotia's ( BNS ) rating to neutral from buy and cut its price objective to 70 Canadian dollars ($48.93) from CA$82.

Bank of Nova Scotia ( BNS ) shares fell over 1% in recent Monday trading.

Price: 47.20, Change: -0.53, Percent Change: -1.11

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copper output from Chile's Codelco down 6% in April
Copper output from Chile's Codelco down 6% in April
Jun 7, 2024
SANTIAGO, June 7 (Reuters) - Copper production from Chile's state-run miner Codelco, the world's largest producer of the metal, dropped 6.1% in April compared to the same month last year to total 95,100 metric tons, data from copper commission Cochilco showed on Friday. Copper output also fell during the month at Chile's Escondida mine, though it edged up 1.9% in...
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
Jun 7, 2024
(Reuters) - A 15-day course of Pfizer's ( PFE ) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's...
Chemed Insider Sold Shares Worth $816,255, According to a Recent SEC Filing
Chemed Insider Sold Shares Worth $816,255, According to a Recent SEC Filing
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Kevin J McNamara, Director, President and CEO, on June 06, 2024, sold 1,500 shares in Chemed ( CHE ) for $816,255. Following the Form 4 filing with the SEC, McNamara has control over a total of 107,049 shares of the company, with 107,049 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/19584/000095017024070509/xslF345X03/ownership.xml Price: 544.96, Change: +0.79,...
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Arcturus Therapeutics Prospective Cystic Fibrosis Treatment Shows Positive Results -- Shares Tumble
Jun 7, 2024
03:16 PM EDT, 06/07/2024 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) slumped more than 29% in Friday trading, despite reporting positive preliminary data from phase 1 and phase 1b study of its ARCT-032 prospective treatment for cystic fibrosis. Appearing at an industry conference in Glasgow, Scotland, executives of the the messenger RNA medicines and vaccines company said the inhaled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved